CN106039109A - 防治寒湿阻络型的类风湿性关节炎的中药药酒 - Google Patents
防治寒湿阻络型的类风湿性关节炎的中药药酒 Download PDFInfo
- Publication number
- CN106039109A CN106039109A CN201610542084.0A CN201610542084A CN106039109A CN 106039109 A CN106039109 A CN 106039109A CN 201610542084 A CN201610542084 A CN 201610542084A CN 106039109 A CN106039109 A CN 106039109A
- Authority
- CN
- China
- Prior art keywords
- radix
- traditional chinese
- chinese medicinal
- liquor
- medicinal liquor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 41
- 238000009825 accumulation Methods 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 88
- 241000903946 Clematidis Species 0.000 claims abstract description 20
- 239000009636 Huang Qi Substances 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims description 28
- 241000131808 Scolopendra Species 0.000 claims description 22
- 241000522620 Scorpio Species 0.000 claims description 22
- 239000009490 scorpio Substances 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 210000000582 semen Anatomy 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 18
- 241000628997 Flos Species 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 15
- 235000021551 crystal sugar Nutrition 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 150000001298 alcohols Chemical class 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 4
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims description 3
- 229910052738 indium Inorganic materials 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims description 3
- 235000021286 stilbenes Nutrition 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 2
- 235000019082 Osmanthus Nutrition 0.000 claims 1
- 241000333181 Osmanthus Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 64
- 238000011282 treatment Methods 0.000 abstract description 49
- 208000002193 Pain Diseases 0.000 abstract description 36
- 230000036407 pain Effects 0.000 abstract description 34
- 229940088597 hormone Drugs 0.000 abstract description 10
- 239000005556 hormone Substances 0.000 abstract description 10
- 208000011580 syndromic disease Diseases 0.000 abstract description 9
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 8
- 230000002588 toxic effect Effects 0.000 abstract description 8
- 230000004069 differentiation Effects 0.000 abstract description 4
- 241000830536 Tripterygium wilfordii Species 0.000 abstract description 3
- 210000003608 fece Anatomy 0.000 abstract description 3
- 235000015398 thunder god vine Nutrition 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 241000427159 Achyranthes Species 0.000 abstract 1
- 244000189799 Asimina triloba Species 0.000 abstract 1
- 235000006264 Asimina triloba Nutrition 0.000 abstract 1
- 235000002566 Capsicum Nutrition 0.000 abstract 1
- 235000009467 Carica papaya Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 241000282994 Cervidae Species 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 241000254173 Coleoptera Species 0.000 abstract 1
- 241000123589 Dipsacus Species 0.000 abstract 1
- 241001071795 Gentiana Species 0.000 abstract 1
- 241001166194 Geranium wilfordii Species 0.000 abstract 1
- 241001506304 Kadsura japonica Species 0.000 abstract 1
- 241000208682 Liquidambar Species 0.000 abstract 1
- 235000006552 Liquidambar styraciflua Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 240000004370 Pastinaca sativa Species 0.000 abstract 1
- 235000017769 Pastinaca sativa subsp sativa Nutrition 0.000 abstract 1
- 239000006002 Pepper Substances 0.000 abstract 1
- 235000016761 Piper aduncum Nutrition 0.000 abstract 1
- 235000017804 Piper guineense Nutrition 0.000 abstract 1
- 244000203593 Piper nigrum Species 0.000 abstract 1
- 235000008184 Piper nigrum Nutrition 0.000 abstract 1
- 241000270273 Ptyas dhumnades Species 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 235000019996 baijiu Nutrition 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 30
- 235000014101 wine Nutrition 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 22
- 208000006820 Arthralgia Diseases 0.000 description 21
- 238000012360 testing method Methods 0.000 description 19
- 210000003734 kidney Anatomy 0.000 description 14
- 210000003205 muscle Anatomy 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 13
- 230000037396 body weight Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 231100000614 poison Toxicity 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 231100000862 numbness Toxicity 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 210000002683 foot Anatomy 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000001015 abdomen Anatomy 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000025747 Rheumatic disease Diseases 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 208000037920 primary disease Diseases 0.000 description 6
- 230000000552 rheumatic effect Effects 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 206010062575 Muscle contracture Diseases 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- 230000003356 anti-rheumatic effect Effects 0.000 description 5
- 239000003435 antirheumatic agent Substances 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 208000006111 contracture Diseases 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 229960003957 dexamethasone Drugs 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000002435 tendon Anatomy 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000000114 Pain Threshold Diseases 0.000 description 4
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- 206010043376 Tetanus Diseases 0.000 description 4
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 4
- 238000011047 acute toxicity test Methods 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000037040 pain threshold Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 231100000019 skin ulcer Toxicity 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010019468 Hemiplegia Diseases 0.000 description 3
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 206010034754 petechiae Diseases 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 230000007096 poisonous effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 201000004647 tinea pedis Diseases 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010010947 Coordination abnormal Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010037544 Purging Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000004680 Rectal Fistula Diseases 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 206010002156 anal fistula Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 208000016290 incoordination Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 229960001929 meloxicam Drugs 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 235000012950 rattan cane Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000272194 Ciconiiformes Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027918 Mononeuropathy multiplex Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010039081 Rheumatoid lung Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000254062 Scarabaeidae Species 0.000 description 1
- 238000003457 Shi epoxidation reaction Methods 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000009257 Visceral Prolapse Diseases 0.000 description 1
- 206010063840 Visceroptosis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940076085 gold Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229940112801 mobic Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 201000002003 mononeuritis multiplex Diseases 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000027062 rheumatoid arthritis interstitial lung disease Diseases 0.000 description 1
- 208000021569 rheumatoid lung disease Diseases 0.000 description 1
- 206010048628 rheumatoid vasculitis Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000000207 volumetry Methods 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000020097 white wine Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/264—Aristolochia (Dutchman's pipe)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Insects & Arthropods (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Developmental Biology & Embryology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种防治寒湿阻络型的类风湿性关节炎的中药药酒,其包括原料药羌活、独活、薏苡仁、威灵仙、桂枝、制川乌、苍术、乌梢蛇、川芎、防风、寻骨风、怀牛膝、木瓜、豨莶草、路路通、海风藤、蜈蚣、全蝎、续断、白酒、红花、炙黄芪、秦艽、鹿筋、雷公藤、老鹳草、桑枝和蜣螂。本发明针对寒湿阻络型类风湿性关节炎的中药药酒,根据中医理论认识,结合病人临床表现,通过辨证论治,组方配伍,起到了散寒除湿、通络止痛的功效,并且有效减少临床激素、非甾体抗炎药导致的毒副作用,日常饮用,具有良好的防治寒湿阻络型类风湿性关节炎的作用,适用于临床推广应用。
Description
本发明涉及中国传统医药技术领域,尤其涉及一种防治寒湿阻络型的类风湿性关节炎的中药药酒。
背景技术
类风湿关节炎(RA)是一种病因未明的慢性、以炎性滑膜炎为主的系统性疾病,其特征是手、足小关节的多关节、对称性、侵袭性关节炎症,经常伴有关节外器官受累及血清类风湿因子阳性,可以导致关节畸形及功能丧失。女性好发,发病率为男性的2~3倍。可发生于任何年龄,高发年龄为40~60岁。
类风湿关节炎治疗的主要目的在于减轻关节炎症反应,抑制病变发展及不可逆骨质破坏,尽可能保护关节和肌肉的功能,最终达到病情完全缓解或低疾病活动度的目标。
该病治疗原则包括患者教育、早期治疗、联合用药、个体化治疗方案以及功能锻炼。药物治疗主要包括非甾类抗炎药、慢作用抗风湿药、免疫抑制剂、免疫和生物制剂及植物药等。
(1)非甾类抗炎药有抗炎、止痛、解热作用,是类风湿关节炎治疗中最为常用的药物,适用于活动期等各个时期的患者。常用的药物包括双氯芬酸、萘丁美酮、美洛昔康、塞来昔布等。
(2)抗风湿药(DMARDs)又被称为二线药物或慢作用抗风湿药物。常用的有甲氨蝶呤,口服或静注;柳氮磺吡啶,从小剂量开始,逐渐递增,以及羟氯喹、来氟米特、环孢素、金诺芬、白芍总苷等。
(3)糖皮质激素激素不作为治疗类风湿关节炎的首选药物,但在下述四种情况可选用激素:①伴随类风湿血管炎包括多发性单神经炎、类风湿肺及浆膜炎、虹膜炎等。②过渡治疗在重症类风湿关节炎患者,可用小量激素快速缓解病情,一旦病情控制,应首先减少或缓慢停用激素。③经正规慢作用抗风湿药治疗无效的患者可加用小剂量激素。④局部应用如关节腔内注射可有效缓解关节的炎症。
(4)生物制剂。目前在类风湿关节炎的治疗上,已经有几种生物制剂被批准上市,并且取得了一定的疗效,尤其在难治性类风湿关节炎的治疗中发挥了重要作用。
(5)植物药。目前,已有多种用于类风湿关节炎的植物药,如雷公藤、白芍总甙、青藤碱等。部分药物对治疗类风湿关节炎具有一定的疗效,但作用机制需进一步研究。
4.免疫净化:类风湿关节炎患者血中常有高滴度自身抗体、大量循环免疫复合物,高免疫球蛋白等,因此,除药物治疗外,可选用免疫净化疗法,可快速去除血浆中的免疫复合物和过高的免疫球蛋白、自身抗体等。如免疫活性淋巴细胞过多,还可采用单个核细胞清除疗法,从而改善T,B细胞及巨噬细胞和自然杀伤细胞功能,降低血液黏滞度,以达到改善症状的目的,同时提高药物治疗的疗效。
随着与抗风湿药的早期联合应用,对关节外病变的治疗以及新疗法的不断出现,使类风湿关节炎的预后已有明显改善。大多数类风湿关节炎患者的病情可得到很好的控制,甚至完全缓解。寒湿阻络型的类风湿性关节炎,西医无对证治疗药物,仅仅针对症状进行抗炎、止痛等治疗,但是其治疗过程相对漫长,长期激素类药物摄入、非甾体抗炎药物的使用,给患者带来较大的药物毒副作用。临床研究标明,中药药物的使用,不仅可以减少西药的使用量,而且可以有效减少西药,特别是激素类药物的毒副作用,甚至对于早期发病患者,可以替代西药进行预防治疗。
临床研究标明,中药药物的使用,不仅可以减少西药的使用量,而且可以有效减少西药,特别是激素类药物的毒副作用,并且,本保健药酒通过内服及外用,可以有效的增强本病的疗效,减少毒副作用,特别是在晚期、重症或长期卧床患者,因合并感染,消化道出血,心、肺或肾病变患者,因西药导致的多脏器功能不全,本药酒体现了其作用的独特性,适用于本病患者治疗期间及辅助治疗保健使用。
发明内容
本发明针对寒湿阻络型类风湿性关节炎,提供一种防治寒湿阻络型类风湿性关节炎的中药药酒,根据中医理论认识,结合病人临床表现,通过辨证论治,组方配伍,起到了散寒除湿、通络止痛的功效,并且有效减少临床激素、非甾体抗炎药导致的毒副作用,日常饮用,具有良好的防治寒湿阻络型类风湿性关节炎的作用,适用于临床推广应用。
为了解决上述技术问题,本发明提供了一种防治寒湿阻络型的类风湿性关节炎的中药药酒,其中包括原料药材羌活、独活、薏苡仁、威灵仙、桂枝、制川乌、苍术、乌梢蛇、川芎、防风、寻骨风、怀牛膝、木瓜、豨莶草、路路通、海风藤、蜈蚣、全蝎、续断、白酒、红花、炙黄芪、秦艽、鹿筋、雷公藤、老鹳草、桑枝和蜣螂。
其中,所述中药药酒中各原料药材的重量分别为羌活20g~35g、独活10g~15g、薏苡仁10g~20g、威灵仙5g~10g、桂枝15g~25g、制川乌10g~15g、苍术15g~30g、乌梢蛇5g~10g、川芎15g~25g、防风20g~30g、寻骨风10g~20g、怀牛膝15g~30g、木瓜10g~20g、豨莶草10g~15g、路路通5g~15g、海风藤10g~15g、蜈蚣5g~9g、全蝎5g~9g、续断10g~15g、白酒5000g、红花20g~30g、炙黄芪25g~40g、秦艽10g~15g、鹿筋10g~20g、雷公藤10g~15g、老鹳草15g~25g、桑枝10g~20g和蜣螂5g~10g。
其中,所述中药药酒中各原料药材的重量分别为羌活25g~30g、独活10g~15g、薏苡仁15g~20g、威灵仙5g~10g、桂枝15g~20g、制川乌10g~15g、苍术20g~25g、乌梢蛇5g~6g、川芎20g~25g、防风20g~25g、寻骨风15g~20g、怀牛膝20g~25g、木瓜15g~20g、豨莶草10g~15g、路路通10g~15g、海风藤10g~15g、蜈蚣5g~6g、全蝎5g~6g、续断10g~15g、白酒5000g、红花25g~30g、炙黄芪30g~35g、秦艽10g~15g、鹿筋15g~20g、雷公藤10g~12g、老鹳草15g~20g、桑枝10g~15g和蜣螂5g~10g。
其中,所述中药药酒中各原料药材的重量分别为羌活30g、独活10g、薏苡仁15g、威灵仙5g、桂枝20g、制川乌10g、苍术20g、乌梢蛇5g、川芎20g、防风25g、寻骨风15g、怀牛膝25g、木瓜15g、豨莶草10g、路路通10g、海风藤10g、蜈蚣5g、全蝎5g、续断10g、白酒5000g、红花25g、炙黄芪35g、秦艽10g、鹿筋15g、雷公藤10g、老鹳草20g、桑枝15g和蜣螂5g。
其中,所述白酒优选酒精度为55%~65%(v/v)。
其中,所述中药药酒还可以加入冰糖、柠檬酸。
所述中药药酒的制备方法具体为:
第一步,中药提取物的制备;
第二步,中药药酒的获取。
所述第一步进一步具体包括:
第a步,各原料药分别粉碎至1mm,按重量称取,混合在一起,用上述的白酒密封浸泡8~10天,所加入的白酒的质量为上述药材混合质量的4~6倍,过滤,获得第一滤液,滤渣备用;
第b步,将第a步过滤获得的滤渣加入到相对于其质量3~5倍醇浓度70%的乙醇溶液中,加热回流提取2小时,过滤,滤液减压浓缩除去溶剂,粉碎并干燥,采用超微粉碎机粉碎至300目~400目,粉碎粉末加入到第一步获得的第一滤液中,获得中药提取物。
其中,所述第二步进一步具体为,在第一步获得的中药提取物中加入余下量的白酒,进一步加入冰糖,混合均匀后装入密闭容器内浸泡15日,获得中药药酒。
有益的技术效果
本发明提供的防治寒湿阻络型类风湿性关节炎的中药药酒,根据中医理论认识,结合病人临床表现,通过辨证论治,组方配伍,起到了散寒除湿、通络止痛的功效,并且有效减少临床激素、非甾体抗炎药导致的毒副作用,日常饮用,具有良好的防治寒湿阻络型类风湿性关节炎的作用,适用于临床推广应用。
具体实施方式
本发明提供了一种防治寒湿阻络型的类风湿性关节炎的中药药酒,其中包括原料药材羌活、独活、薏苡仁、威灵仙、桂枝、制川乌、苍术、乌梢蛇、川芎、防风、寻骨风、怀牛膝、木瓜、豨莶草、路路通、海风藤、蜈蚣、全蝎、续断、白酒、红花、炙黄芪、秦艽、鹿筋、雷公藤、老鹳草、桑枝和蜣螂。
类风湿性关节炎的发生,西医对其病因尚未认清,尽管有大量的治疗措施,但是仅仅是根据症状进行有针对性的治疗,中医对本病自古就有较为广泛的认识,归为痹症范畴,并根据其临床表现分为寒湿痹阻型和肝肾不足型,其治疗各不相同,人生活居处,受环境影响、受饮食及素体情况影响,而关节常与外界环境所接触,又易受寒湿所侵袭,风寒湿为外感六淫,人体正气不足时,侵袭关节,邪气留恋,日久变为寒湿阻络证型的关节炎,因此,散寒除湿止痛是治疗本病的关键。
本发明药酒针对其中寒湿痹阻型类风湿性关节炎进行组方配伍,通过制备中药药酒,在本病的治疗期间可以协助西药及康复治疗,减少西药毒副作用,增加西药疗效,在预防和调理本病期间,可以起到很好的辅助治疗保健作用。
本发明药酒使用羌活、独活、秦艽、威灵仙、海风藤、雷公藤、寻骨风、制川乌祛风湿,止痹痛,以羌活、独活、秦艽为君药组,三药合用,祛风湿、止痹痛效果显著,现代医学研究,三药配合,其有效成分能够很好的降低类风湿因子,改善局部红肿热痛的症状;本发明中药药酒使用乌梢蛇、蜈蚣、全蝎、蜣螂、路路通,入经络搜风祛邪,其中乌梢蛇、蜈蚣、全蝎、蜣螂为虫类药,性走窜,具有很强的通经络的功效,蜈蚣、全蝎中含有特殊蛋白成分,对于炎性反应的抑制作用显著,减少炎性细胞渗出,路路通有较好的通经络功效,与虫类药配合使用,增强其功效,诸药合用为臣药组;此外,本发明药酒还使用续断、桑枝、桂枝、海风藤、雷公藤、木瓜,有疏利关节的作用,枝者肢也,藤着通也,续断、桑枝、桂枝等药对于关节功能的恢复具有较好的调节作用,海风藤、雷公藤二药,含有的有效成分,特别是雷公藤甲素,具有很好的抗炎作用,木瓜养肝柔筋,缓急止痛,诸药合用,有助于改善关节功能受限,起到很好的治疗作用,共为佐药;此外,加入薏苡仁、苍术、防风、老鹳草祛湿,其中薏苡仁淡渗利湿,苍术、防风温化寒湿、燥湿健脾,老鹳草解毒除湿,针对激素使用后的不良反应具有很好的改善作用,此外,药酒中加入少许活血行气,滋养肝肾的药物,如补脾益气的炙黄芪,行气活血的川芎、红花,滋补肝肾的怀牛膝、鹿筋、豨莶草,起到扶正固本的作用,药酒使用高度数的白酒,白酒本是一味中药,有很好的活血通络的功效,并且全方在白酒浸泡后,入经络起效,全方合用,具有很好的散寒除湿、通络止痛的功效。
进一步优选,所述中药药酒仅由上述原料药制备而成。
羌活:拉丁名Notopterygii Rhizoma et Radix,味辛、苦,性温,入肾、膀胱经,具有解表散寒、祛风胜湿、止痛的功效,具有风寒夹湿表证,症见恶寒发热、头痛如裹,颈项脊背强痛,肢体沉重,骨节酸痛,风寒湿痹等证。
独活:拉丁名Angelicae Pubescentis Radix,味辛、苦,性微温,归肝、肾、膀胱经,具有祛风胜湿;散寒止痛的功效,用于风寒湿痹;腰膝疼痛;少阴伏风头痛,头痛齿痛等证。
薏苡仁:味甘、淡,性微寒,入肺、脾、大肠经,有健脾止泻,利水除痹,排疮脓的作用,主要用于湿困肺胃之泄泻;湿邪侵渍肌肤之全身水肿,小便不利;湿热阻于气血之痹通以及毒热蕴结于肺肠之肺痈、肠痈等证。
威灵仙:拉丁名clematidis radix et rhizoma,味辛、咸,性温,有小毒,入膀胱经,具有祛风除湿,通络止痛,消痰水,散癖积的功效,主治痛风顽痹、风湿痹痛,肢体麻木,腰膝冷痛,筋脉拘挛,屈伸不利,脚气,疟疾,症瘕积聚,破伤风,扁桃体炎,诸骨鲠咽。
桂枝:拉丁名cinnamomi ramulus,为樟科植物肉桂干燥嫩枝味辛、甘,性温,入肺、心、膀胱经,有解肌发汗,温经散寒,通脉,化气行水的作用。主要用于风寒表征,但其发散之力不及麻黄,也可用于汗出恶风的表虚症状,还用于风湿痹阻之周身疼痛、重着麻木;气阴两虚之惊悸、目眩;心阳衰弱之心悸、头眩、肢冷,蓄血,胸痹;脾肾阳虚之淡饮水湿滞留等症状。
制川乌:味辛、苦,性热,归心、肝、肾、脾经,具有祛风除湿,温经止痛的功效,主治风寒湿痹,关节疼痛,心腹冷痛,寒疝作痛,麻醉止痛等证。
苍术:味辛、苦,性温,入脾、胃、肝经,有燥湿健脾,祛风胜湿,明目的作用,主要用于湿阻中焦之腹痛泻痢,脾胃不和之腹胀疼痛,呕吐纳呆;肝胃不和之腹胁胀痛、呕吐泛酸;以及寒湿外郁经络之风寒湿痹等证。
乌梢蛇:味甘,性平,归肝经,具有祛风,通络,止痉的功效。用于风湿顽痹,麻木拘挛,中风口眼歪斜,半身不遂,抽搐痉挛,破伤风,麻风疥癣,瘰疬恶疮等证。
川芎:味辛,性温,归肝、胆、心包经,具有活血行气,祛风止痛的功效,主治月经不调;经闭痛经;产后瘀滞腥痛;症瘕肿块;胸胁疼痛;头痛眩晕;风寒湿痹;跌打损伤;痈疽疮疡等证。
防风:味辛、甘,性微温,入肺、肝、脾、膀胱经,有散寒解表,胜湿止痛,祛风止痉,止痒的作用,主要用于外感风寒证及寒邪郁闭,内热郁结之表寒里热证等。
寻骨风:味辛、苦,性平,具有肝,胃经,具有祛风除湿,活血通络;止痛的功效。主治风湿痹痛;肢体麻木;筋骨拘挛;脘腹疼痛;跌打伤痛;外伤出血;乳痈及多种化脓性感染、腹痛,疟疾等证。
怀牛膝:味苦、酸,性平,具有活血散瘀,祛湿利尿,清热解毒的功效。主治淋病,尿血,妇女经闭,症瘕,风湿关节痛,脚气,水肿,痢疾,疟疾,白喉,痈肿,跌打损伤等证。
木瓜:性平、微寒,味甘,归肝、脾经,具有平肝舒筋,和胃化湿的功效,主治湿痹拘挛,腰膝关节酸重疼痛,吐泻转筋,脚气水肿等证。
豨莶草:拉丁名Siegesbeckiae Herba,味寒、辛、苦,归肝经、肾经,具有祛风湿,利关节,解毒的功效,主治风湿痹痛、筋骨无力、腰膝酸软、四肢麻痹、半身不遂、风疹湿疮等证。
路路通:味苦、性平,归肝、肾经,具有祛风活络,利水通经,主治关节痹痛、麻木拘挛,水肿胀满,乳少,闭经等证。
海风藤:味辛、苦,性微温,归肝经,具有祛风湿,通经络,止痹痛的功效,主治风寒湿痹,肢节疼痛,筋脉拘挛,屈伸不利等证。
蜈蚣:味辛,性温,有毒,归肝经。具有祛风,定惊,攻毒,散结的功效。主治中风,惊痫,破伤风,百日咳,瘰疬,结核,癥积瘤块,疮疡肿毒,风癣,白秃,痔漏,烫伤等证。
全蝎:味辛,性平,归肝经,具有息风镇痉,攻毒散结,通络止痛的功效,主治小儿惊风,抽搐痉挛,中风口歪,半身不遂,破伤风,风湿顽痹,偏正头痛,疮疡,瘰疬等证。
续断:味辛,性微温,归肝、肾经,具有补肝肾;强筋骨;调血脉;续折伤;止崩漏的功效,主治腰背酸痛;肢节痿痹;跌扑创伤、损筋折骨、胎动漏红、血崩、遗精、带下、痈疽疮肿等证。
红花:性温,味辛,入、心、肝经,具有活血通经,祛瘀止痛的作用,用于闭经,痛经,恶露不行,症瘕痞块,跌扑损伤,疮疡肿痛等症。
炙黄芪:拉丁名astragali radix,味甘,性温,入脾、肺经,有补益脾土,升举阳气、固表止汗,托疮生肌等作用,主要用于脾肺气虚所致之乏力食少便溏,心悸气短,中气下陷之脏器下垂,气不摄血之崩漏便血,久泻脱肛;表虚不固之自汗盗汗,气血不足等证。
秦艽:味辛、苦,性微寒,归胃经、肝经、胆经,具有祛风湿,舒筋络,清虚热的功效,主治风湿痹痛,筋脉拘挛,骨节酸痛,日晡潮热,小儿疳积发热等证。
鹿筋:性温,味淡、微咸,归肝、肾二经,具有补肾阳、壮筋骨的功效。主治劳损过度、风湿关节痛、子宫寒冷、阳痿、遗精等证。
雷公藤:拉丁名Tripterygium wilfordii Hook.f,味苦、辛,性凉,归肝、肾经。功效祛风除湿、通络止痛、消肿止痛、解毒杀虫。用于湿热结节、癌瘤积毒,临床上用其治疗麻风反应、类风湿性关节炎等,有抗肿瘤、抗炎等作用。
老鹳草:味辛、苦,性平,归肝、肾、脾经,具有祛风湿,通经络,止泻利的功效,用于风湿痹痛,麻木拘挛,筋骨酸痛,泄泻痢疾等证。
桑枝:味微苦,性平,归肝经,具有祛风湿,利关节的功效,主治风湿痹痛,肩臂,关节酸痛麻木等证。
蜣螂:拉丁名Scarabaeidae,味咸,性寒。具有解毒,消肿,通便的功效。主治疮疡肿毒,痔漏,便秘等证。
所述中药药酒中各原料药材的重量分别为羌活20g~35g、独活10g~15g、薏苡仁10g~20g、威灵仙5g~10g、桂枝15g~25g、制川乌10g~15g、苍术15g~30g、乌梢蛇5g~10g、川芎15g~25g、防风20g~30g、寻骨风10g~20g、怀牛膝15g~30g、木瓜10g~20g、豨莶草10g~15g、路路通5g~15g、海风藤10g~15g、蜈蚣5g~9g、全蝎5g~9g、续断10g~15g、白酒5000g、红花20g~30g、炙黄芪25g~40g、秦艽10g~15g、鹿筋10g~20g、雷公藤10g~15g、老鹳草15g~25g、桑枝10g~20g和蜣螂5g~10g。
进一步优选,所述中药药酒中各原料药材的重量分别为羌活25g~30g、独活10g~15g、薏苡仁15g~20g、威灵仙5g~10g、桂枝15g~20g、制川乌10g~15g、苍术20g~25g、乌梢蛇5g~6g、川芎20g~25g、防风20g~25g、寻骨风15g~20g、怀牛膝20g~25g、木瓜15g~20g、豨莶草10g~15g、路路通10g~15g、海风藤10g~15g、蜈蚣5g~6g、全蝎5g~6g、续断10g~15g、白酒5000g、红花25g~30g、炙黄芪30g~35g、秦艽10g~15g、鹿筋15g~20g、雷公藤10g~12g、老鹳草15g~20g、桑枝10g~15g和蜣螂5g~10g。
最优选,所述中药药酒中各原料药材的重量分别为羌活30g、独活10g、薏苡仁15g、威灵仙5g、桂枝20g、制川乌10g、苍术20g、乌梢蛇5g、川芎20g、防风25g、寻骨风15g、怀牛膝25g、木瓜15g、豨莶草10g、路路通10g、海风藤10g、蜈蚣5g、全蝎5g、续断10g、白酒5000g、红花25g、炙黄芪35g、秦艽10g、鹿筋15g、雷公藤10g、老鹳草20g、桑枝15g和蜣螂5g。
所述白酒优选酒精度为55%~65%(v/v),优选为60%(v/v)。
所述中药药酒还可以加入冰糖、柠檬酸等调配口感,冰糖的加入量优选为1000ml中药药酒中加入5~8g,柠檬酸的添加量优选为1000ml中药药酒中加入0.8~1.2g。
所述中药药酒的制备方法具体为:
第一步,中药提取物的制备;
第二步,中药药酒的获取。
所述第一步进一步具体包括:
第a步,各原料药分别粉碎至1mm,按重量称取,混合在一起,用上述的白酒密封浸泡8~10天,所加入的白酒的质量为上述药材混合质量的4~6倍,过滤,获得第一滤液,滤渣备用;
第b步,将第a步过滤获得的滤渣加入到相对于其质量3~5倍醇浓度70%的乙醇溶液中,加热回流提取2小时,过滤,滤液减压浓缩除去溶剂,粉碎并干燥,采用超微粉碎机粉碎至300目~400目,粉碎粉末加入到第一步获得的第一滤液中,获得中药提取物。
所述第二步进一步具体为,在第一步获得的中药提取物中加入余下量的白酒,进一步加入冰糖,混合均匀后装入密闭容器内浸泡15日,获得中药药酒。
以下采用实施例来详细说明本发明的实施方式,借此对本发明如何应用技术手段来解决技术问题,并达成技术效果的实现过程能充分理解并据以实施。
实施例1药酒1
称取羌活30g、独活10g、薏苡仁15g、威灵仙5g、桂枝20g、制川乌10g、苍术20g、乌梢蛇5g、川芎20g、防风25g、寻骨风15g、怀牛膝25g、木瓜15g、豨莶草10g、路路通10g、海风藤10g、蜈蚣5g、全蝎5g、续断10g、红花25g、炙黄芪35g、秦艽10g、鹿筋15g、雷公藤10g、老鹳草20g、桑枝15g和蜣螂5g分别粉碎至1mm,混合在一起,用2.5kg60%(v/v)白酒密封浸泡10天,过滤,获得第一滤液,滤渣备用,将前面过滤获得的滤渣加入到相对于其质量4倍醇浓度70%的乙醇溶液中,加热回流提取2小时,过滤,滤液减压浓缩除去溶剂,粉碎并干燥,采用超微粉碎机粉碎至300目,粉碎粉末加入到第一滤液中,获得中药提取物,在获得的中药提取物中加入2.5kg的白酒,进一步加入冰糖,1000ml中药药酒中加入6g冰糖,混合均匀后装入密闭容器内浸泡15日,获得中药药酒。
实施例2药酒2
称取羌活25g、独活10g、薏苡仁15g、威灵仙5g、桂枝15g、制川乌10g、苍术20g、乌梢蛇5g、川芎20g、防风20g、寻骨风15g、怀牛膝20g、木瓜15g、豨莶草10g、路路通10g、海风藤10g、蜈蚣5g、全蝎5g、续断10g、红花25g、炙黄芪30g、秦艽10g、鹿筋15g、雷公藤10g、老鹳草15g、桑枝10g和蜣螂5g分别粉碎至1mm,混合在一起,用2.5kg60%(v/v)白酒密封浸泡10天,过滤,获得第一滤液,滤渣备用,将前面过滤获得的滤渣加入到相对于其质量4倍醇浓度70%的乙醇溶液中,加热回流提取2小时,过滤,滤液减压浓缩除去溶剂,粉碎并干燥,采用超微粉碎机粉碎至300目,粉碎粉末加入到第一滤液中,获得中药提取物,在获得的中药提取物中加入2.5kg的白酒,进一步加入冰糖,1000ml中药药酒中加入6g冰糖,混合均匀后装入密闭容器内浸泡15日,获得中药药酒。
实施例3药酒3
称取羌活30g、独活15g、薏苡仁20g、威灵仙10g、桂枝20g、制川乌15g、苍术25g、乌梢蛇6g、川芎25g、防风25g、寻骨风20g、怀牛膝25g、木瓜20g、豨莶草15g、路路通15g、海风藤15g、蜈蚣6g、全蝎6g、续断15g、红花30g、炙黄芪35g、秦艽15g、鹿筋20g、雷公藤12g、老鹳草20g、桑枝15g和蜣螂10g分别粉碎至1mm,混合在一起,用2.5kg60%(v/v)白酒密封浸泡10天,过滤,获得第一滤液,滤渣备用,将前面过滤获得的滤渣加入到相对于其质量4倍醇浓度70%的乙醇溶液中,加热回流提取2小时,过滤,滤液减压浓缩除去溶剂,粉碎并干燥,采用超微粉碎机粉碎至300目,粉碎粉末加入到第一滤液中,获得中药提取物,在获得的中药提取物中加入2.5kg的白酒,进一步加入冰糖,1000ml中药药酒中加入6g冰糖,混合均匀后装入密闭容器内浸泡15日,获得中药药酒。
实施例4药物毒理学试验
本发明中药药酒使用羌活、独活、薏苡仁、威灵仙、桂枝、制川乌、苍术、乌梢蛇、川芎、防风、寻骨风、怀牛膝、木瓜、豨莶草、路路通、海风藤、蜈蚣、全蝎、续断、白酒、红花、炙黄芪、秦艽、鹿筋、雷公藤、老鹳草、桑枝和蜣螂。等药,经过文献研究及临床观察,可能存在毒性或者副作用的中药有乌梢蛇、制川乌、蜈蚣、全蝎、蜣螂等药,根据本发明最优组合用量,制川乌10g、乌梢蛇5g、蜈蚣5g、全蝎5g、蜣螂5g,各药物单副药用量均小于国家药典规定用量,而根据其制备方法可知,经过药酒制备后,结合其临床使用方法,其用量约为临床单日、单次用量的6%,因此可知,前述可能存在毒性或副作用的药物用量远远小于临床规定用量,因此其安全性是符合规定的,故开展全方配伍的急毒性及长期毒性研究。
急性毒性试验
实验动物:ICR清洁级小鼠40只,22~24g,雌雄各半。动物来源:山东中医药大学实验动物中心提供,购入后适应性饲养3d。
受试药物
本发明药物:本发明实施例1制备的中药药酒,处理得到相当于含生药浓度为0.125g/ml。
实验方法
取ICR小鼠20只,雌雄各半,随机分为4组,其中两组为内服急毒性试验研究,另外两组为皮肤刺激性实验
1)内服毒性试验
两组小鼠,灌胃体积为0.4ml/20g,每日给药3次,间隔4小时,连续给药7d,观察给药后所有动物的自主活动、呼吸、食欲、粪便、以及其他指标;观察期间,如有小鼠死亡,则立即进行剖检。
2)皮肤刺激性实验
两组小鼠,后背备皮1cm×1cm,酒精消毒后自然晾干,发明组给与本发明实施例1中药药酒配置的生药浓度0.125g/ml的药液外涂,1ml次,对照组给与生理盐水外涂,1ml/次,用药后观察皮肤情况,记录皮疹、肤色、出血点等。
试验结果
1)一般状态观察
给药后,观察记录小鼠行为活动,连续7d,无明显异常现象,各天然孔腔无异常分泌物,摄食饮水均正常,尿液粪便正常,小鼠无死亡。
2)皮肤刺激性试验
通过观察,发明组小鼠皮肤无红肿、无皮疹、无出血点等,与对照组无明显变化。
结论
一般认为最大耐受量相当于人临床日用剂量100倍以上而动物无死亡,无明显毒性反应情况出现时,该药是安全的。本发明药酒的临床拟用量为6.25g/60kg/d,即0.1042g/kg/d,根据实验小鼠最大耐受量7.5g/kg/d,根据小鼠与人给药剂量换算比9.01计算,此耐受量是本发明药酒临床拟用量的648.5倍,此外,进行皮肤刺激性实验,无红肿、皮疹等过敏反应。因此,可以肯定,本药品临床应用是安全的。
小鼠长期毒性试验
受试药物与配药
同急毒性试验,得到相当于含生药浓度为0.125g/ml。
实验动物
同急毒性试验,60只。
实验方法
(1)分组与给药途径
选取40只ICR小鼠,按体重随机分为对照组1(灌胃按0.2ml/20g体重)、对照组2(灌胃按0.1ml/20g体重)、本发明高剂量组(灌胃按0.2ml/20g体重)、低剂量组(灌胃按0.1ml/20g体重),相应剂量为2.5g/kg/d,1.25g/kg/d。给药途径及给药剂量与急毒性相同。
另取20只ICR小鼠,按体重随机分为对照组和发明组。
(2)给药方法
本发明药酒各剂量组给药2次/日,上午10时,按实验要求分别灌胃给药,间隔6小时,对照组1及高剂量组,按体积0.2ml/20g灌胃给药,对照组2及低剂量组,按体积0.1ml/20g灌胃给药。每周称1次体重,并根据体重调整给药量,连续给药42d后停药(临床用药1个疗程为7~14天),恢复观察期为停药后14d。
2)皮肤刺激性实验
两组小鼠,后背备皮1cm×1cm,酒精消毒后自然晾干,发明组给与本发明实施例1中药药酒配置的生药浓度0.025g/ml的药液外涂,1ml次,对照组给与生理盐水外涂,1ml/次,用药后观察皮肤情况,记录皮疹、肤色、出血点等。
实验结果
小鼠灌胃给予本发明高剂量2.5g/kg/d,(临床成人拟用剂量51.76倍)、本发明低剂量1.7g/kg/d,(临床成人拟用剂量25.88倍),2次/日,连续给药42d后与对照组比较各项检测指标如一般状态、体重、进食量、饮水量、脏器系数和组织病理学等,未见明显的毒性敏感指标和毒性靶器官;停药恢复2周后,本发明药酒高、低剂量组小鼠各项检测指标均属正常,未见本发明药酒产生迟发性毒性反应和蓄积性毒性反应,此外,进行皮肤刺激性实验,无红肿、皮疹等过敏反应。试验结果说明本发明药酒长期应用对小鼠无明显毒副作用,临床成人拟用剂量和疗程处于安全范围。
实施例5临床研究
一般资料
2015年3月至2015年12月,我科门诊就诊并随访治疗的患者237例,随机分为两组,治疗组117例,男81例,女86例,年龄37~74,平均54.8±7.1岁;病程7~21年,平均13.2±3.2年;对照组120例,男62例,女58例,年龄39~75,平均57.4±6.9岁;病程8~22年,平均12.4±3.1年。两组患者一般资料无显著性差异,P>0.05。
诊断标准
西医诊断标准
①晨僵
②至少一个关节活动是疼痛或有压痛
③至少一个关节肿胀(软组织肥厚或者积液)
④对称性关节肿胀,同时侵犯机体两侧的同一关节,远策指间关节的累及不能满足此项标准
⑤骨隆起部或关节附近伸侧的皮下结节
⑥标准的X线锁键
⑦类风湿因子阳性
⑧滑膜液中粘蛋白凝固不佳
⑨具有下述滑膜病理学改变中三个或更多:明显的绒毛增生;表层滑膜细胞增生及呈栅栏状;明显的慢性炎细胞(主要为淋巴细胞和浆细胞)浸润及形成淋巴结的趋势;表层或间质内致密的纤维素沉积;灶性坏死。
⑩皮下结节中的组织学改变应显示中心区细胞坏死灶,围绕着栅状增生的巨噬细胞及最外层的慢性炎细胞浸润。
中医诊断标准
符合西医诊断标准患者,同时符合以下中医辨证标准的,为肝肾不足型类风湿性关节炎。
肝肾阴虚不足的症状:视物昏花,头晕目眩,肢体麻木,神疲力乏,睡眠欠佳,食欲不振,脉沉细,舌淡。
排除标准
①治疗前1w内使用过任何治疗RA药物;
②合并心、脑、肝、肾、肺及造血系统严重疾病以及过敏体质者;
③罹患除RA外其他可能影响关节功能疾病者;
④卧床或使用轮椅者。
治疗方法
治疗组用本发明中药药酒内服加每日擦洗病变关节,每日擦洗5-8次,擦洗后,用温水洗净。本发明实施例1制备的药酒1,每日服用两次,每次50ml,中午、晚上服用;
对照组口服美洛昔康(商品名:莫比可,上海勃林格殷格翰药业有限公司生产):7.5mg/次,2次/d口服;雷公藤片(黄石飞云制药有限公司生产):10mg/次,2次/d口服,均饭后1h使用。
两组均连续治疗3个月,之后随访统计疗效。治疗过程中不用其他对临床观察有干扰的药物。
观察指标
(1)症状及体征:晨僵时间(h),双手平均握力(mmHg),20m步行时间(s),病变涉及关节个数及关节疼痛、肿胀、触痛程度和关节功能指数。关节疼痛、肿胀、触痛功能指数计算方法:I级计1分,II级计2分,III级计3分,IV级计4分,病变关节总积分/涉及关节数目=相应项目的指数。关节炎症程度分级标准参照《中药新药临床研究指导原则》拟定。
(2)理化指标:类风湿因子(RF),C反应蛋白(CRP),血沉(ESR),免疫球蛋白(IgG,IgA,IgM),补体C3、血红蛋白含量(HGB)、X线检查。各项指标与治疗前及治疗结束后各监测1次。
(3)观察安全性指标(血常规、肝功、肾功)及不良反应。
疗效评定标准
显效:关节肿痛明显减轻甚至消失,活动功能改善,实验室指标明显改善,观察指标下降60%以上,无关节畸形加重及放射学进展恶化;
有效:关节肿痛好转,活动功能有所改善,实验室指标有改善,观察指标下降30%以上,无关节畸形加重及放射学进展恶化;
无效:实验室指标无明显变化,观察指标下降不足30%,或下降高于30%,但存在关节畸形加重或放射学进展恶化。
统计学方法
应用SPSS17.0统计学软件进行统计,计量数据用均数±标准差表示,组间差异用两个独立样本t检验。
结果
两组患者临床疗效比较
治疗组显效率和有效率优于对照组,P<0.05,见表1
表1两组患者治疗前后症状及体征变化的比较
组别 | N | 显效 | 有效 | 无效 | 总有效率% |
治疗组 | 117 | 48 | 56 | 13 | 88.89* |
对照组 | 120 | 31 | 60 | 29 | 75.83 |
与对照组比较,*P<0.05
两组患者治疗前后症状及体征变化的比较
两组患者治疗后症状及体征均有明显改善,与治疗前比较差异显著(P<0.05);治疗组患者治疗后关节疼痛、压痛指数与对照组治疗后比较无显著性差异(P>0.05),其余指标与对照组治疗后比较有显著性差异(P<0.05或P<0.01),见表2、表3。
表2两组患者治疗前后症状变化的比较
与对照组比较,*P<0.05
表3两组患者治疗前后体征变化的比较
与对照组比较,*P<0.05
两组治疗前后实验室指标的变化
两组治疗前实验室各指标比较差异无统计学意义(P>0.05),两组治疗后较实验室指标均有明显改善(P<0.05);治疗后两组有显著性差异(P<0.05)。见表4
表4两组患者治疗前后实验室指标变化的比较一
与对照组比较,*P<0.05
表5两组患者治疗前后实验室指标变化的比较二
与对照组比较,*P<0.05
不良反应
治疗组治疗过程中未出现明显不良反应,肝肾功能无异常;对照组治疗过程中,9例出现不同程度的不良反应,其发生率为8.9%,其中食欲不振6例,胃痛3例,粒细胞减少7例,丙氨酸转氨酶(ALT)升高8例。两组不良反应发生率比较有极显著性差异P<0.01。
结论
通过临床观察,肝肾不足型类风湿性关节炎患者通过内服本发明中药药酒,关节局部擦洗,经过三个月的治疗,其疗效显著,优于对照药物,对各项症状、体征的改善均优于对照组,对于实验室指标的改善,尤为显著。
综合分析,本发明中药药酒对于肝肾不足型类风湿性关节炎的治疗具有很好的治疗作用,进一步经过实验室研究后,得出相关实验室证据,为进一步研发、推广本发明药酒的临床应用奠定基础。
实施例6动物研究
实验用药
本发明实施例1制备的中药药酒1,处理得到中药生药有效含量为0.35g/ml;
阿司匹林片:南京金陵制药(集团)有限公司产品;
地塞米松:江苏省黄海制药厂产品。
实验动物
SD雄性大鼠(体重250~300g),ICR小鼠,雄雌各半,体重20±2g。
方法
对大鼠急性非特异性炎症抗炎作用
将30只大鼠随机分成3组,分别为对照组、阿司匹林组(350mg/kg)、本发明中药药酒组。每只鼠右足跖皮下注射1.5%的角叉菜胶0.1ml致炎,并于致炎前1h按40ml/kg体重给予每组大鼠相应的试验药品灌胃,对照组给予同等体积的蒸馏水。同时采用容积测定法测定致炎前和致炎后0.5、1、2、3、4、5h足跖容积变化,以致炎前足容积的差值作为肿胀度。结果见表5。
表5大鼠足爪肿胀的影响(n=10,)
与空白组比较,*P<0.05;与阿司匹林组比较,#P<0.05
对大鼠免疫性炎症抗炎作用
将30只大鼠随机分3组,分别为对照组、地塞米松针组,本发明中药药酒组。于致炎前1h分别给对照组大鼠和本发明中药药酒组大鼠灌胃,容积40ml/kg,地塞米松组皮下注射0.05ml/kg,且在致炎后18h、24h连续给药2次,将完全弗氏佐剂0.05ml注射入大鼠右足皮下致炎,并于致炎前及致炎后6、18、24、48h分别测量大鼠右足体积。结果见表6。
表6各组大鼠足爪肿胀率的比较(n=10,)
与空白组比较,*P<0.05;与地塞米松组比较,#P<0.05
镇痛试验
取小鼠30只,雄雌各半,随机分组,对照组灌胃生理盐水,药酒组灌胃本发明中药药酒组。阳性对照用阿司匹林片水溶液灌胃给药。给药前先测定小鼠的痛阈值,将恒温水浴调至55℃,放一金属盘,使其底部接触水面,加热后作为热刺激。用秒表记录小鼠投入热板至出现舔后足的时间(s)为痛阈值(以小于30s者为合格)。给药后1h再测定,如痛阈值超出60s以60s计算。结果见表7。
表7镇痛试验比较
组别 | 痛阈值(s) |
对照组 | 14.7±4.2 |
阿司匹林组 | 29.1±4.8* |
药酒组 | 33.4±12.8* |
与空白组比较,*P<0.05
对小鼠耳廓肿胀度的影响
取小鼠30只随机分组,分组给药方法同2,末次给药后30min,各组小鼠用0.05ml二甲苯在每鼠左耳前后两面,右耳留作对照。1h后将小鼠处死,沿耳廓基线剪下两耳。用9mm打孔器分别在同一部位打下圆耳片,用组织天平称重,每鼠左耳片减去右耳片的重量即为肿胀度。与对照组比较,检验有无显著性差异。结果见表8。
表8对小鼠耳廓肿胀度的影响
组别 | 耳廓肿胀度(mm) |
对照组 | 24.8±5.1 |
地塞米松组 | 11.7±5.0 |
药酒组 | 10.9±4.7 |
结论
通过动物实验研究,模拟人体类风湿性关节炎发病的机制,采用本发明中药药酒进行相关干预,证实了本发明中药制剂具有很好的抗炎、止痛、消肿作用,为临床推广本发明中药药酒的使用,提供了可靠的实验室证据。
所有上述的首要实施这一知识产权,并没有设定限制其他形式的实施这种新产品和/或新方法。本领域技术人员将利用这一重要信息,上述内容修改,以实现类似的执行情况。但是,所有修改或改造基于本发明新产品属于保留的权利。
以上所述,仅是本发明的较佳实施例而已,并非是对本发明作其它形式的限制,任何熟悉本专业的技术人员可能利用上述揭示的技术内容加以变更或改型为等同变化的等效实施例。但是凡是未脱离本发明技术方案内容,依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与改型,仍属于本发明技术方案的保护范围。
Claims (9)
1.一种防治寒湿阻络型的类风湿性关节炎的中药药酒,其特征在于:包括原料药材羌活、独活、薏苡仁、威灵仙、桂枝、制川乌、苍术、乌梢蛇、川芎、防风、寻骨风、怀牛膝、木瓜、豨莶草、路路通、海风藤、蜈蚣、全蝎、续断、白酒、红花、炙黄芪、秦艽、鹿筋、雷公藤、老鹳草、桑枝和蜣螂。
2.如权利要求1所述的防治寒湿阻络型的类风湿性关节炎的中药药酒,其特征在于:各原料药材的重量分别为羌活20g~35g、独活10g~15g、薏苡仁10g~20g、威灵仙5g~10g、桂枝15g~25g、制川乌10g~15g、苍术15g~30g、乌梢蛇5g~10g、川芎15g~25g、防风20g~30g、寻骨风10g~20g、怀牛膝15g~30g、木瓜10g~20g、豨莶草10g~15g、路路通5g~15g、海风藤10g~15g、蜈蚣5g~9g、全蝎5g~9g、续断10g~15g、白酒5000g、红花20g~30g、炙黄芪25g~40g、秦艽10g~15g、鹿筋10g~20g、雷公藤10g~15g、老鹳草15g~25g、桑枝10g~20g和蜣螂5g~10g。
3.如权利要求1或2所述的防治寒湿阻络型的类风湿性关节炎的中药药酒,其特征在于:各原料药材的重量分别为羌活25g~30g、独活10g~15g、薏苡仁15g~20g、威灵仙5g~10g、桂枝15g~20g、制川乌10g~15g、苍术20g~25g、乌梢蛇5g~6g、川芎20g~25g、防风20g~25g、寻骨风15g~20g、怀牛膝20g~25g、木瓜15g~20g、豨莶草10g~15g、路路通10g~15g、海风藤10g~15g、蜈蚣5g~6g、全蝎5g~6g、续断10g~15g、白酒5000g、红花25g~30g、炙黄芪30g~35g、秦艽10g~15g、鹿筋15g~20g、雷公藤10g~12g、老鹳草15g~20g、桑枝10g~15g和蜣螂5g~10g。
4.如权利要求1至3所述的防治寒湿阻络型的类风湿性关节炎的中药药酒,其特征在于:各原料药材的重量分别为羌活30g、独活10g、薏苡仁15g、威灵仙5g、桂枝20g、制川乌10g、苍术20g、乌梢蛇5g、川芎20g、防风25g、寻骨风15g、怀牛膝25g、木瓜15g、豨莶草10g、路路通10g、海风藤10g、蜈蚣5g、全蝎5g、续断10g、白酒5000g、红花25g、炙黄芪35g、秦艽10g、鹿筋15g、雷公藤10g、老鹳草20g、桑枝15g和蜣螂5g。
5.如权利要求1至4所述的防治寒湿阻络型的类风湿性关节炎的中药药酒,其特征在于:所述白酒优选酒精度为55%~65%(v/v)。
6.如权利要求1至5所述的防治寒湿阻络型的类风湿性关节炎的中药药酒,其特征在于:所述中药药酒还可以加入冰糖、柠檬酸。
7.权利要求1至6所述中药药酒的制备方法,其特征在于,包括:
第一步,中药提取物的制备;
第二步,中药药酒的获取。
8.如权利要求7所述中药药酒的制备方法,其特征在于:所述第一步进一步具体包括,
第a步,各原料药分别粉碎至1mm,按重量称取,混合在一起,用上述的白酒密封浸泡8~10天,所加入的白酒的质量为上述药材混合质量的4~6倍,过滤,获得第一滤液,滤渣备用;
第b步,将第a步过滤获得的滤渣加入到相对于其质量3~5倍醇浓度70%的乙醇溶液中,加热回流提取2小时,过滤,滤液减压浓缩除去溶剂,粉碎并干燥,采用超微粉碎机粉碎至300目~400目,粉碎粉末加入到第一步获得的第一滤液中,获得中药提取物。
9.如权利要求7或8所述中药药酒的制备方法,其特征在于:所述第二步进一步具体为,在第一步获得的中药提取物中加入余下量的白酒,进一步加入冰糖,混合均匀后装入密闭容器内浸泡15日,获得中药药酒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610542084.0A CN106039109A (zh) | 2016-07-11 | 2016-07-11 | 防治寒湿阻络型的类风湿性关节炎的中药药酒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610542084.0A CN106039109A (zh) | 2016-07-11 | 2016-07-11 | 防治寒湿阻络型的类风湿性关节炎的中药药酒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106039109A true CN106039109A (zh) | 2016-10-26 |
Family
ID=57185228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610542084.0A Pending CN106039109A (zh) | 2016-07-11 | 2016-07-11 | 防治寒湿阻络型的类风湿性关节炎的中药药酒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106039109A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107760533A (zh) * | 2017-11-16 | 2018-03-06 | 张兴保 | 一种鹿筋保健酒及其制备方法 |
CN108420998A (zh) * | 2018-05-02 | 2018-08-21 | 北京华医正健生物科技有限公司 | 一种药酒及其制备方法 |
CN109528950A (zh) * | 2018-12-13 | 2019-03-29 | 洪湖市中医医院 | 一种驱寒通痹片及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105497851A (zh) * | 2015-12-29 | 2016-04-20 | 青岛蓝图文化传播有限公司市南分公司 | 一种治疗风湿的中药浸酒配方 |
-
2016
- 2016-07-11 CN CN201610542084.0A patent/CN106039109A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105497851A (zh) * | 2015-12-29 | 2016-04-20 | 青岛蓝图文化传播有限公司市南分公司 | 一种治疗风湿的中药浸酒配方 |
Non-Patent Citations (2)
Title |
---|
吴新卫;等: "系列痹症胶囊药效学的实验研究", 《江苏临床医学杂志》 * |
欧艳娟: "补肝肾祛风湿法治疗老年晚期类风湿关节炎63例", 《中国老年学杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107760533A (zh) * | 2017-11-16 | 2018-03-06 | 张兴保 | 一种鹿筋保健酒及其制备方法 |
CN108420998A (zh) * | 2018-05-02 | 2018-08-21 | 北京华医正健生物科技有限公司 | 一种药酒及其制备方法 |
CN109528950A (zh) * | 2018-12-13 | 2019-03-29 | 洪湖市中医医院 | 一种驱寒通痹片及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN105535694A (zh) | 一种治疗高尿酸血症的中药组合物 | |
CN102000164A (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
CN106039109A (zh) | 防治寒湿阻络型的类风湿性关节炎的中药药酒 | |
CN103405582A (zh) | 改善类风湿关节炎关节肿痛的中药组合物 | |
CN103071138A (zh) | 一种治疗慢性胃炎的中药组合物及制备方法和应用 | |
CN102302733B (zh) | 治疗卵巢囊肿的内服中药组合物 | |
CN104815318A (zh) | 一种治疗痛风的中药制剂 | |
CN103908600B (zh) | 治疗类风湿性关节炎湿热痹阻证的外用药物及制备方法 | |
CN103083592A (zh) | 一种治疗痛风性关节炎的中药 | |
CN104784538A (zh) | 一种治疗糖尿病的中药制剂及制备方法 | |
CN104706839A (zh) | 一种治疗风湿性关节炎的中药制剂 | |
CN101194968B (zh) | 一种治疗荨麻疹的中药制剂 | |
CN103908603B (zh) | 一种治疗痛风的中药组合物及其制备方法 | |
CN103386101B (zh) | 一种治疗非特异性膀胱炎的中药制剂及其制备方法 | |
CN102198261A (zh) | 一种治疗老年慢性结肠炎的中药制剂及其制备方法 | |
CN103100063B (zh) | 一种治疗湿热型胆囊结石的中药 | |
CN106860659A (zh) | 一种治疗寒痧症病的组合物及其制备方法 | |
CN106177639A (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
CN105213876A (zh) | 一种治疗失眠药物及其制作方法 | |
CN105106634A (zh) | 一种治疗急性阑尾炎的中药制剂及其应用 | |
CN104800675A (zh) | 用于治疗活动期溃疡性结肠炎的药物 | |
CN103735725B (zh) | 用于治疗猪风湿病的药物及其制备方法 | |
CN103520575A (zh) | 一种治疗脾胃湿热型慢性胃炎的中药制剂及制备方法 | |
CN102641422B (zh) | 一种治疗急性荨麻疹的中成药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161026 |